PharmaShots | Incisive News in 3 Shots

Subscribe Now

Seres Therapeutics

Seres Therapeutics’ SER-155 Secures the US FDA’s Breakthrough Therapy Designation to Reduce Bloodstream Infections

Seres Therapeutics’ SER-155 Secures the US FDA’s Breakthrough Therapy Designation to Reduce Bloodstream Infections

December 10, 2024

Seres Therapeutics and Nestlé Health Science Present P-III Study (ECOSPOR IV) Results Vowst for Prevention of Recurrence of C. Difficile Infection at DDW 2023

Seres Therapeutics and Nestlé Health Science Present P-III Study (ECOSPOR IV) Results Vowst for Prevention of Recurrence of C. Dif...

May 9, 2023

Seres Therapeutics and Nestlé Health Science Receive the US FDA’s Approval of VOWST for the Prevention of Recurrence of C. Difficile Infection

Seres Therapeutics and Nestlé Health Science Receive the US FDA’s Approval of VOWST for the Prevention of Recurrence of C. Diffici...

April 27, 2023

Seres Therapeutics Reports P-III Trial (ECOSPOR IV) Results of SER-109 for the Prevention of Recurrent C. Difficile Infection

Seres Therapeutics Reports P-III Trial (ECOSPOR IV) Results of SER-109 for the Prevention of Recurrent C. Difficile Infection

February 15, 2023

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us